Merck & Co., Inc. (NYSE:MRK – Get Free Report)’s share price traded down 0.1% on Tuesday after UBS Group lowered their price target on the stock from $142.00 to $136.00. UBS Group currently has a buy rating on the stock. Merck & Co., Inc. traded as low as $107.81 and last traded at $108.52. 1,976,492 shares were traded during mid-day trading, a decline of 77% from the average session volume of 8,746,816 shares. The stock had previously closed at $108.59.
A number of other research analysts have also weighed in on the stock. Evercore ISI upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Tuesday, July 30th. Morgan Stanley boosted their price target on shares of Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research report on Thursday, July 11th. Barclays reduced their price target on shares of Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday. Truist Financial reduced their price target on shares of Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Bank of America reduced their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $133.00.
Get Our Latest Research Report on Merck & Co., Inc.
Institutional Inflows and Outflows
Merck & Co., Inc. Price Performance
The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22. The firm has a market capitalization of $279.32 billion, a P/E ratio of 122.53, a P/E/G ratio of 1.60 and a beta of 0.39. The firm’s 50 day simple moving average is $114.85 and its two-hundred day simple moving average is $123.45.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.12. The business had revenue of $16.10 billion during the quarter, compared to the consensus estimate of $15.87 billion. Merck & Co., Inc. had a net margin of 21.99% and a return on equity of 40.69%. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.06) earnings per share. As a group, analysts predict that Merck & Co., Inc. will post 8.01 earnings per share for the current year.
Merck & Co., Inc. Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, October 7th. Stockholders of record on Monday, September 16th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 2.79%. The ex-dividend date of this dividend was Monday, September 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.22%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Momentum Trades for October With Ample Upside Ahead
- 3 Stocks to Consider Buying in October
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- How to Invest in Biotech Stocks
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.